The use of drugs in influencing human fetal metabolism.
D000308:Adrenocortical Hyperfunction / Q000188:drug therapy; D000818:Animals; D001805:Blood Transfusion, Intrauterine / Q000009:adverse effects; D003409:Congenital Hypothyroidism / Q000188:drug therapy; D004899:Erythroblastosis, Fetal / Q000628:therapy; D004967:Estrogens / Q000627:therapeutic use; D000431:Ethanol / Q000627:therapeutic use; D005321:Extraembryonic Membranes; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D005333:Fetus / Q000187:drug effects; D005938:Glucocorticoids / Q000627:therapeutic use; D003932:Heroin / Q000627:therapeutic use; D006801:Humans; D006819:Hyaline Membrane Disease / Q000188:drug therapy; D006854:Hydrocortisone / Q000097:blood; D007020:Hypoprothrombinemias / Q000188:drug therapy; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007556:Isoxsuprine / Q000627:therapeutic use; D007567:Jaundice, Neonatal / Q000517:prevention & control; D008168:Lung / Q000187:drug effects; D008431:Maternal-Fetal Exchange; D010634:Phenobarbital / Q000627:therapeutic use; D011247:Pregnancy; D011663:Pulmonary Surfactants; D011817:Rabbits; D051381:Rats; D013974:Thyroxine / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D004967:Estrogens; D005938:Glucocorticoids; D011663:Pulmonary Surfactants; D014807:Vitamin D; D000431:Ethanol; D003932:Heroin; D013974:Thyroxine; D007556:Isoxsuprine; D006854:Hydrocortisone; D010634:Phenobarbital